Abiopharma

Clinical trial NCT07707466 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2026-08-31 → 2026-07-31 3. primary completion date: 2026-08-31 → 2026-07-31

Clinical trial NCT06042751 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2026-07-31 → 2026-05-27 3. primary completion date: 2026-01-31 → 2026-05-10 4. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT07255807 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2025-12-01 → 2026-01-09

Clinical trial NCT06487559 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. completion date: 2027-10-01 → 2027-02-01 3. primary completion date: 2027-10-01 → 2027-02-01 4. enrollment: 20 → 3 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT07549490: start date: 2026-08-19 → 2026-08-20.

Clinical trial NCT06205602: status: RECRUITING → ACTIVE_NOT_RECRUITING.

Clinical trial NCT06031272 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2026-06-30 → 2026-06-25

Clinical trial NCT07440290 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-02-01 → 2026-04-01

Clinical trial NCT07547813 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-04-01 → 2026-05-13

Clinical trial NCT07176689 updates: 1. completion date: 2031-01-14 → 2031-02-26 2. primary completion date: 2031-01-14 → 2031-02-26

Clinical trial NCT06052631: start date: 2026-08-19 → 2026-08-20.

Clinical trial NCT07092020 updates: 1. status: RECRUITING → COMPLETED 2. completion date: 2027-10-01 → 2026-07-27 3. primary completion date: 2027-10-01 → 2026-07-27 4. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT06254950 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. primary completion date: 2026-09-30 → 2026-07-14 3. enrollment: 207 → 213 participants 4. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT06048133: primary completion date: 2026-07-01 → 2026-12-01.

Clinical trial NCT07146022: status: RECRUITING → ACTIVE_NOT_RECRUITING.